Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.
Anticancer Res
; 36(1): 455-60, 2016 Jan.
Article
em En
| MEDLINE
| ID: mdl-26722081
ABSTRACT
BACKGROUND:
Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) represent novel, effective tools in the management of advanced-stage non-small cell lung cancer (NSCLC). We aimed to evaluate the incidence and predictive role of EGFR gene amplification in patients with advanced-stage NSCLC treated with EGFR-TKIs. PATIENTS ANDMETHODS:
The study included 290 patients with advanced-stage (IIIB or IV) NSCLC. Multiplex ligation-dependent probe amplification (MLPA) and polymerase chain reaction (PCR) were used for detection of EGFR gene amplification and EGFR mutations, respectively.RESULTS:
EGFR amplification was detected in 26 (9.0%) patients. EGFR amplification was found more frequently in patients harboring the EGFR mutation (p<0.001). No significant corelation between EGFR gene amplification and survival was observed.CONCLUSION:
EGFR gene amplification is associated with EGFR gene mutation. EGFR gene amplification is not a feasible predictive biomarker for treatment with EGFR-TKIs in patients with advanced-stage NSCLC.Palavras-chave
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Amplificação de Genes
/
Carcinoma Pulmonar de Células não Pequenas
/
Receptores ErbB
/
Neoplasias Pulmonares
Tipo de estudo:
Prognostic_studies
Limite:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article